Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hemogenyx PharmaceuticalsHOPHF 25 Debt-to-Equity is 1.68 as of Dec. 2025, which is 60% above its 10-year median of 1.05. GuruFocus rates HOPHF with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 964 Biotechnology companies, Hemogenyx Pharmaceuticals ranks worse than 92.84% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Hemogenyx Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
HOPHF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.62 Med: 1.05 Max: 2.92
Current: 1.68
During the past 11 years, the highest Debt-to-Equity Ratio of Hemogenyx Pharmaceuticals was 2.92. The lowest was -3.62. And the median was 1.05.
HOPHF's Debt-to-Equity is ranked worse than 92.84% of 964
companies
in the Biotechnology industry
Industry Median: 0.16
vs HOPHF: 1.68
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Hemogenyx Pharmaceuticals Debt-to-Equity Related Terms
Hemogenyx Pharmaceuticals Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOPHF vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hemogenyx Pharmaceuticals Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Hemogenyx Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemogenyx Pharmaceuticals (HOPHF) has a Debt-to-Equity of 1.68 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Hemogenyx Pharmaceuticals and its competitors. This is 60% above median its historical median of 1.05. According to the industry distribution chart, Hemogenyx Pharmaceuticals ranks #895 out of 964 companies in the Biotechnology industry, placing it in the top 92.8%.
Is Hemogenyx Pharmaceuticals' Debt-to-Equity too high?
Hemogenyx Pharmaceuticals' current Debt-to-Equity of 1.68 is 60% above median its 10-year median of 1.05. The Biotechnology industry median Debt-to-Equity is 0.16. Hemogenyx Pharmaceuticals' value of 1.68 is 950% above this industry median. Based on the distribution chart, Hemogenyx Pharmaceuticals ranks #895 out of 964 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hemogenyx Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Hemogenyx Pharmaceuticals' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hemogenyx Pharmaceuticals ranks #895 out of 964 companies for Debt-to-Equity. This places Hemogenyx Pharmaceuticals in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Hemogenyx Pharmaceuticals' value of 1.68 is 950% above this benchmark. While the company's 10-year median is 1.05 vs. the industry median of 0.16, Hemogenyx Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hemogenyx Pharmaceuticals's current Debt-to-Equity of 1.68 is 950% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Hemogenyx Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hemogenyx Pharmaceuticals's current Debt-to-Equity is 1.68, which is 60% above median its own 10-year median of 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemogenyx Pharmaceuticals stock overvalued right now?
Hemogenyx Pharmaceuticals (HOPHF) has a current Debt-to-Equity of 1.68. The current Debt-to-Equity is 1.68, which is 60% above median its 10-year median of 1.05 and 950% above the Biotechnology industry median of 0.16. Hemogenyx Pharmaceuticals' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Hemogenyx Pharmaceuticals (HOPHF), the current Debt-to-Equity is 1.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.
25GF Score
Get the complete analysis for HOPHF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOPHF has been successfully added to your 
